MXPA03001425A - Compuestos farmaceuticos. - Google Patents

Compuestos farmaceuticos.

Info

Publication number: MXPA03001425A
Authority: MX; Mexico
Prior art keywords: pharmaceutical compounds; pharmaceutical; compounds
Prior art date: 2000-08-17

Application number

MXPA03001425A

Other languages

English (en)

Inventor

Julian Blagg

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-08-17

Filing date

2001-08-08

Publication date

2003-06-06

2000-08-17 Priority claimed from GB0020346A external-priority patent/GB0020346D0/en

2000-11-09 Priority claimed from GB0027409A external-priority patent/GB0027409D0/en

2000-12-04 Priority claimed from GB0029556A external-priority patent/GB0029556D0/en

2001-08-08 Application filed by Pfizer filed Critical Pfizer

2003-06-06 Publication of MXPA03001425A publication Critical patent/MXPA03001425A/es

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Pulmonology (AREA)
Dermatology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Hematology (AREA)
Diabetes (AREA)
Reproductive Health (AREA)
Immunology (AREA)
Rheumatology (AREA)
Epidemiology (AREA)
Gynecology & Obstetrics (AREA)
Ophthalmology & Optometry (AREA)
Pain & Pain Management (AREA)
Vascular Medicine (AREA)
Pregnancy & Childbirth (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Surgery (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)

MXPA03001425A 2000-08-17 2001-08-08 Compuestos farmaceuticos. MXPA03001425A (es)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
GB0020346A GB0020346D0 (en)	2000-08-17	2000-08-17	Pharmaceuticals
GB0027409A GB0027409D0 (en)	2000-11-09	2000-11-09	Pharmaceuticals
GB0029556A GB0029556D0 (en)	2000-12-04	2000-12-04	Pharmaceuticals
PCT/IB2001/001425 WO2002014285A1 (en)	2000-08-17	2001-08-08	Substituted imidazoles as tafia inhibitors

Publications (1)

Publication Number	Publication Date
MXPA03001425A true MXPA03001425A (es)	2003-06-06

Family

ID=27255849

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MXPA03001425A MXPA03001425A (es)	2000-08-17	2001-08-08	Compuestos farmaceuticos.

Country Status (38)

Country	Link
EP (1)	EP1311488B1 (es)
JP (2)	JP4119746B2 (es)
KR (1)	KR20030022412A (es)
CN (1)	CN1443173A (es)
AP (1)	AP1375A (es)
AR (1)	AR035580A1 (es)
AT (1)	ATE447557T1 (es)
AU (1)	AU2001276605A1 (es)
BG (1)	BG107330A (es)
BR (1)	BR0113289A (es)
CA (1)	CA2419633C (es)
CY (1)	CY1109693T1 (es)
CZ (1)	CZ2003388A3 (es)
DE (1)	DE60140368D1 (es)
DK (1)	DK1311488T3 (es)
DO (1)	DOP2001000233A (es)
EA (1)	EA005532B1 (es)
EE (1)	EE200300070A (es)
ES (1)	ES2334101T3 (es)
HR (1)	HRP20030103A2 (es)
HU (1)	HUP0303763A3 (es)
IL (1)	IL153225A0 (es)
IS (1)	IS6638A (es)
MA (1)	MA26940A1 (es)
MX (1)	MXPA03001425A (es)
NO (1)	NO20030706L (es)
NZ (1)	NZ522823A (es)
OA (1)	OA12362A (es)
PA (1)	PA8525401A1 (es)
PE (1)	PE20020352A1 (es)
PL (1)	PL361054A1 (es)
PT (1)	PT1311488E (es)
SI (1)	SI1311488T1 (es)
SK (1)	SK1732003A3 (es)
SV (1)	SV2002000602A (es)
TN (1)	TNSN01126A1 (es)
UY (1)	UY26889A1 (es)
WO (1)	WO2002014285A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE0103272D0 (sv)	2001-09-28	2001-09-28	Astrazeneca Ab	Chemical compounds
US6713496B2 (en)	2002-01-22	2004-03-30	Pfizer Inc	3-(imidazolyl)-2-alkoxypropanoic acids
IL162677A0 (en) *	2002-01-22	2005-11-20	Pfizer	3-(Imidazolyl)-2-alkoxypropanoic acids as tafia inhibitors
MXPA04005940A (es)	2002-01-22	2004-09-13	Pfizer	Acidos 3-(imidazolil)-2-aminopropanoicos.
AU2004235488A1 (en) *	2003-04-29	2004-11-11	Universitat Zurich	Nepsilon and/or nalpha derivatized, metal and organic protected l-histidine for coupling to biomolecules for highly efficient labeling with [M(OH2)3(CO)3]+ by fac coordination
SE0302853D0 (sv) *	2003-10-29	2003-10-29	Astrazeneca Ab	Chemical compounds
AU2004290499C1 (en) *	2003-11-03	2011-02-24	Probiodrug Ag	Combinations useful for the treatment of neuronal disorders
WO2005051384A1 (en) *	2003-11-25	2005-06-09	Pfizer Limited	Stabilised pharmaceutical compositions
CA2604912A1 (en) *	2005-04-18	2006-10-26	Bayer Schering Pharma Aktiengesellschaft	Use of tafi inhibitors for enhanced myocardial reperfusion and facilitated pci
DE102005049385A1 (de) *	2005-10-15	2007-04-19	Sanofi-Aventis Deutschland Gmbh	Imidazolderivate als Inhibitoren von TAFIa
HRP20150514T1 (hr) *	2006-12-06	2015-09-11	Sanofi	DERIVATI SULFAMIDA KAO INHIBITORI TAFIa
EP2262783A2 (en) *	2008-02-21	2010-12-22	Sanofi-Aventis	Covalently binding imaging probes
JPWO2010050525A1 (ja)	2008-10-29	2012-03-29	大正製薬株式会社	ＴＡＦＩａ阻害活性を有する化合物
FR2947266B1 (fr) *	2009-06-26	2011-06-17	Servier Lab	Nouveaux derives d'acide 2-mercaptocyclopentanecarboxylique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP2548872B1 (en)	2010-03-18	2016-09-28	Daiichi Sankyo Company, Limited	Cyclopropanecarboxylic acid derivative
ES2643132T3 (es) *	2010-03-18	2017-11-21	Daiichi Sankyo Company, Limited	Derivado de imidazol cicloalquilo sustituido
GEP201706614B (en) *	2011-05-17	2017-02-10	Pharmasyntez	Compounds, pharmaceutical compositions and a method for the prophylaxis and treatment of the adhesion process
JP5996647B2 (ja) *	2011-07-22	2016-09-21	カンブレックスカルルスクーガアクチボラケットＣａｍｂｒｅｘＫａｒｌｓｋｏｇａＡｂ	４−置換イミダゾールの新規な調製プロセス
WO2013039202A1 (ja) *	2011-09-15	2013-03-21	第一三共株式会社	新規アクリル酸誘導体
BR112015029667A2 (pt)	2013-06-10	2017-07-25	Sanofi Sa	derivados de ureia macrocíclica como inibidores de tafia, sua preparação e seus usos como produtos farmacêuticos
WO2017062468A1 (en)	2015-10-07	2017-04-13	Mitobridge, Inc.	Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
FR3046793B1 (fr) *	2016-01-14	2018-01-05	Les Laboratoires Servier	Nouveaux derives de phosphinanes et azaphosphinanes, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US20190117624A1 (en)	2016-03-29	2019-04-25	Daiichi Sankyo Company, Limited	Therapeutic agent for inflammatory bowel diseases
JP6925367B2 (ja)	2016-04-13	2021-08-25	ミトブリッジ，インコーポレーテッド	Ｐｐａｒアゴニスト、化合物、医薬組成物、及びその使用方法
CN113943255B (zh) *	2020-07-17	2024-08-06	深圳信立泰药业股份有限公司	一种手性3-(4-环丙基-2,5-二氧杂咪唑啉-4-基)丙酸的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS6163661A (ja) *	1984-09-05	1986-04-01	Microbial Chem Res Found	ヒスタジン関連化合物
US5993815A (en) *	1996-11-08	1999-11-30	University Of Vermont	Methods and compositions for inhibiting the activation of thrombin-activatable fibrinolysis inhibitor (TAFI)
SE9901572D0 (sv) *	1999-05-03	1999-05-03	Astra Ab	New compounds

2001
- 2001-08-08 HR HR20030103A patent/HRP20030103A2/hr not_active Application Discontinuation
- 2001-08-08 CN CN01813131A patent/CN1443173A/zh active Pending
- 2001-08-08 DE DE60140368T patent/DE60140368D1/de not_active Expired - Lifetime
- 2001-08-08 KR KR10-2003-7002279A patent/KR20030022412A/ko not_active Ceased
- 2001-08-08 BR BR0113289-0A patent/BR0113289A/pt not_active Application Discontinuation
- 2001-08-08 SI SI200130950T patent/SI1311488T1/sl unknown
- 2001-08-08 HU HU0303763A patent/HUP0303763A3/hu unknown
- 2001-08-08 IL IL15322501A patent/IL153225A0/xx unknown
- 2001-08-08 AT AT01954264T patent/ATE447557T1/de active
- 2001-08-08 AU AU2001276605A patent/AU2001276605A1/en not_active Abandoned
- 2001-08-08 SK SK173-2003A patent/SK1732003A3/sk unknown
- 2001-08-08 ES ES01954264T patent/ES2334101T3/es not_active Expired - Lifetime
- 2001-08-08 EA EA200201239A patent/EA005532B1/ru not_active IP Right Cessation
- 2001-08-08 OA OA1200300039A patent/OA12362A/fr unknown
- 2001-08-08 EE EEP200300070A patent/EE200300070A/xx unknown
- 2001-08-08 EP EP01954264A patent/EP1311488B1/en not_active Expired - Lifetime
- 2001-08-08 MX MXPA03001425A patent/MXPA03001425A/es active IP Right Grant
- 2001-08-08 CA CA2419633A patent/CA2419633C/en not_active Expired - Fee Related
- 2001-08-08 PT PT01954264T patent/PT1311488E/pt unknown
- 2001-08-08 PL PL36105401A patent/PL361054A1/xx not_active Application Discontinuation
- 2001-08-08 DK DK01954264T patent/DK1311488T3/da active
- 2001-08-08 WO PCT/IB2001/001425 patent/WO2002014285A1/en not_active Ceased
- 2001-08-08 CZ CZ2003388A patent/CZ2003388A3/cs unknown
- 2001-08-08 NZ NZ522823A patent/NZ522823A/en unknown
- 2001-08-08 JP JP2002519428A patent/JP4119746B2/ja not_active Expired - Fee Related
- 2001-08-14 PA PA20018525401A patent/PA8525401A1/es unknown
- 2001-08-15 AR ARP010103900A patent/AR035580A1/es unknown
- 2001-08-15 UY UY26889A patent/UY26889A1/es not_active Application Discontinuation
- 2001-08-15 PE PE2001000815A patent/PE20020352A1/es not_active Application Discontinuation
- 2001-08-16 TN TNTNSN01126A patent/TNSN01126A1/fr unknown
- 2001-08-16 AP APAP/P/2001/002250A patent/AP1375A/en active
- 2001-08-16 SV SV2001000602A patent/SV2002000602A/es unknown
- 2001-11-14 DO DO2001000233A patent/DOP2001000233A/es unknown
2002
- 2002-11-28 IS IS6638A patent/IS6638A/is unknown
- 2002-11-28 BG BG107330A patent/BG107330A/xx unknown
2003
- 2003-02-04 MA MA27025A patent/MA26940A1/fr unknown
- 2003-02-14 NO NO20030706A patent/NO20030706L/no not_active Application Discontinuation
2008
- 2008-02-27 JP JP2008045382A patent/JP4778531B2/ja not_active Expired - Fee Related
2009
- 2009-12-30 CY CY20091101349T patent/CY1109693T1/el unknown

Also Published As

Publication number	Publication date
NO20030706L (no)	2003-04-15
EE200300070A (et)	2005-02-15
CA2419633A1 (en)	2002-02-21
ATE447557T1 (de)	2009-11-15
DK1311488T3 (da)	2010-01-04
DOP2001000233A (es)	2002-05-15
UY26889A1 (es)	2002-03-22
PE20020352A1 (es)	2002-05-11
EA005532B1 (ru)	2005-04-28
JP2008169224A (ja)	2008-07-24
IL153225A0 (en)	2003-07-06
EP1311488A1 (en)	2003-05-21
PA8525401A1 (es)	2002-04-25
JP4778531B2 (ja)	2011-09-21
KR20030022412A (ko)	2003-03-15
AR035580A1 (es)	2004-06-16
TNSN01126A1 (fr)	2005-11-10
OA12362A (en)	2004-04-07
BG107330A (en)	2003-06-30
NZ522823A (en)	2004-11-26
AP1375A (en)	2005-03-03
HRP20030103A2 (en)	2003-04-30
IS6638A (is)	2002-11-28
ES2334101T3 (es)	2010-03-05
SV2002000602A (es)	2002-10-24
BR0113289A (pt)	2003-06-17
JP4119746B2 (ja)	2008-07-16
MA26940A1 (fr)	2004-12-20
SI1311488T1 (sl)	2010-01-29
NO20030706D0 (no)	2003-02-14
CA2419633C (en)	2011-05-10
DE60140368D1 (de)	2009-12-17
EP1311488B1 (en)	2009-11-04
PT1311488E (pt)	2009-12-30
EA200201239A1 (ru)	2003-08-28
WO2002014285A1 (en)	2002-02-21
CZ2003388A3 (cs)	2004-03-17
CY1109693T1 (el)	2014-08-13
AP2001002250A0 (en)	2001-09-30
PL361054A1 (en)	2004-09-20
AU2001276605A1 (en)	2002-02-25
HUP0303763A2 (hu)	2004-04-28
HUP0303763A3 (en)	2004-06-28
JP2004506044A (ja)	2004-02-26
CN1443173A (zh)	2003-09-17
SK1732003A3 (en)	2004-08-03

Publication	Publication Date	Title
ITTO20000779A0 (it)	2000-08-04	Composizioni farmaceutiche.
ITTO20010005A0 (it)	2001-01-09	Formulazione farmaceutica.
MX242679B (es)	2006-12-14	Antranilamidas insecticidas.
MXPA03001425A (es)	2003-06-06	Compuestos farmaceuticos.
NO20026196L (no)	2003-02-24	Kinazolinditosylatsalt-forbindelser
IS6686A (is)	2003-01-16	Hýdrógel-drifið lyfjaskömmtunarform
DK1619192T3 (da)	2010-03-29	Arylkondeserede azapolycykliske forbindelser
FI20000004A0 (fi)	2000-01-03	Flavonoidilääke...
NL1019181A1 (nl)	2002-04-18	Gestabiliseerd metalloceen-polypropeen.
NL1017973A1 (nl)	2001-11-13	Inrichting.
ES1046587Y (es)	2001-06-01	Felpudo modular.
DK1331972T3 (da)	2007-11-05	Farmaceutiske præparater
CH695519A5 (de)	2006-06-15	Sperrstromthyristor.
ATE372338T1 (de)	2007-09-15	Deshalogenverbindungen
NO20030303D0 (no)	2003-01-20	Kalsilytiske forbindelser
NO20031837D0 (no)	2003-04-24	Kalsilytiske forbindelser
NO20023508D0 (no)	2002-07-23	Kalsilyttiske forbindelser
MXPA03001857A (es)	2003-06-04	Composicones medicinales.
ES1046656Y (es)	2001-06-16	Microplanta de transferencia de residuos solidos urbanos.
NL1014850A1 (nl)	2001-10-09	Grafkist.
ES1045851Y (es)	2001-04-01	Cubitera.
IT249307Y1 (it)	2003-04-08	Ciabatta.
ES1047836Y (es)	2001-10-01	Hidrobicicleta.
ES1047010Y (es)	2001-07-16	Portalamparas.
ES1047305Y (es)	2001-08-16	Embudo anti-rebosamiento.

Legal Events

Date	Code	Title	Description
2007-04-20	FG	Grant or registration